" class="no-js "lang="en-US"> Clinical Trials Archives - Page 5 of 35 - Medtech Alert
Friday, September 26, 2025

Sort by:

Date

Top Post

Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome

Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder

Lyndra Therapeutics, a clinical-stage biopharmaceutical company working to make daily pills a thing of the […]

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

Telix Pharmaceuticals today announces that it has entered into an agreement with Bayer AG (Bayer) […]

Senhwa Biosciences Received Taiwan FDA IND Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe COVID-19

Senhwa Biosciences, a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and […]

OliX Pharmaceuticals Announces Positive Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar Treatment

OliX Pharmaceuticals, a leading developer of RNAi therapeutics, today announced positive headline results of a […]

Alphyn Biologics Presents Pediatric Data from Atopic Dermatitis Trial at European Society for Pediatric Dermatology Congress

Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, will present for the first […]

Actinium Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community

Actinium Pharmaceuticals, a leader in the development of targeted radiotherapies, today announced that the positive […]

Avidity Biosciences Announces Positive Topline Data from Myotonic Dystrophy Trial

Avidity Biosciences, a biopharmaceutical company committed to delivering a new class of RNA therapeutics called […]

Junshi Biosciences Announces Primary Endpoint Met in RENOTORCH Study of Toripalimab for 1st-line Treatment of Advanced Renal Cell Carcinoma

Shanghai Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization […]

Vertex Announces FDA Approval for TRIKAFTA in Children With Cystic Fibrosis

Vertex Pharmaceuticals has announced the U.S. Food and Drug Administration (FDA) approved the expanded use […]

Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease

Direct Biologics, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more